LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT) reports that Professor René Bernards, Netherlands Cancer Institute, Amsterdam has presented new data from promising drug combinations of LIXTE’s lead clinical cancer compound, LB-100 at the Annual Meeting of America Association for Cancer Research in New Orleans, LA.
Bernards has discussed his approach to developing more effective cancer therapies. The initial studies reveal that the vigorous activation of several ocogenic signaling pathways by LB-100 is associated with marked increases in DNA damage and mitotic stress.
John S. Kovach MD, Founder and CEO of LIXTE Biotechnology Holdings, Inc., said “we are delighted to be working with Professor Bernards and his team. Professor Bernards’ insights and contributions enable us to take full advantage of the unique anti-cancer properties of LB-100. His creativity in developing new anti-cancer drug combinations has already had a significant impact on cancer care. His current observations of unexpected synergy of LB-100 with a variety of standard agents and with investigational compounds with only modest activity on their own are promising leads to a new approach to cancer chemotherapy.”